NCT03374475 - A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

January 5, 2018

Primary Completion Date

April 29, 2019

Study Completion Date

April 29, 2019

Conditions

Depressive Disorder, Major

Interventions

DRUG

JNJ-42847922 20mg

Participants will swallow 20 mg (2\*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.

DRUG

JNJ-42847922 40mg

Participants will swallow 40 mg (2\*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.

DRUG

Placebo

All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.

Trial Locations (14)

2170

Clinical Pharmacology Unit, Merksem

2800

SGS Phase 1 Unit AZ St-Maarten, Mechelen

10117

Charite Research Organisation GmbH, Berlin

10629

Emovis GmbH, Berlin

19053

Somni Bene GmbH, Schwerin

30625

Fraunhofer-Institut für Toxikologie und Experimentelle Medizin, Hanover

33143

Qps-Mra, Llc, Miami

92078

Artemis Institute for Clinical Research, San Marcos

92103

Artemis Institute for Clinical Research, San Diego

2333 CL

Centre for Human Drug Research, Leiden

FY2 0JH

MAC Clinical Research, Blackpool

L34 1BH

MAC Clinical Research, Liverpool

NW10 7EW

Hammersmith Medicines Research, London

M13 9NQ

MAC Clinical Research, Manchester

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY